OXFORD, United Kingdom, April 28, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the ...
OXFORD, United Kingdom, April 28, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the ...
OXFORD, United Kingdom, April 28, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the ...
OXFORD, United Kingdom, April 28, 2017 (GLOBE NEWSWIRE) -- Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the ...
LEXINGTON, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company ...
LEXINGTON, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company ...
LEXINGTON, Mass., April 28, 2017 (GLOBE NEWSWIRE) -- Curis, Inc. (Nasdaq:CRIS), a biotechnology company ...
SAN DIEGO, April 28, 2017 (GLOBE NEWSWIRE) -- Invivoscribe® Technologies Inc., a global company ...
SAN DIEGO, April 28, 2017 (GLOBE NEWSWIRE) -- Invivoscribe® Technologies Inc., a global company ...
SAN DIEGO, April 28, 2017 (GLOBE NEWSWIRE) -- Invivoscribe® Technologies Inc., a global company ...
Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than ...
Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than ...
Approval in newly diagnosed FLT3-mutated AML represents the first new treatment in more than ...